SuperworthStandard Biotools market cap LAB
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $237.7M
- Highest close in our data
- $1.3B
- Mar 2014
Standard Biotools is worth $237.7M at the close on Oct 23, 2026, at $0.61 a share.
That is down 56% over the last year and down 39% over five years.
Its highest close in our data was $1.3B in Mar 2014.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $237.7M | $237.7M | $599.9M | −55% |
| 2025 | $530.7M | $350M | $677.5M | −22% |
| 2024 | $677.5M | $148.5M | $956.4M | +286% |
| 2023 | $175.5M | $122.9M | $240.8M | +89% |
| 2022 | $92.8M | $81M | $300.6M | −69% |
| 2021 | $299.8M | $290.6M | $555.5M | −33% |
| 2020 | $444.7M | $87.4M | $621.9M | +90% |
| 2019 | $233.7M | $162.1M | $941.7M | −31% |
| 2018 | $337.8M | $191.1M | $337.8M | +48% |
| 2017 | $227.6M | $92.3M | $236.9M | +7% |
| 2016 | $212M | $128.1M | $304.9M | −32% |
| 2015 | $311.2M | $228.6M | $1.3B | −67% |
| 2014 | $936.3M | $621.5M | $1.3B | −7% |
| 2013 | $1B | $366.6M | $1B | +190% |
| 2012 | $348.1M | $255.5M | $363.1M | +31% |
| 2011 | $266.4M | $242.9M | $299.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Standard Biotools' size, closest first, today.
| Company | Market cap |
|---|---|
| LABStandard Biotools | $237.7M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| LFVNLifevantage | $73.4M |
| ABUSArbutus Biopharma | $831M |
| SPROSpero Therapeutics | $64.6M |
| Peer median | $570.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Standard Biotools
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.